{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:08:43Z","timestamp":1784862523526,"version":"3.55.0"},"reference-count":47,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2019,2,28]]},"DOI":"10.2217\/fon-2018-0546","type":"journal-article","created":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T11:03:48Z","timestamp":1542193428000},"page":"591-599","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Apalutamide and its Use in the Treatment of Prostate Cancer"],"prefix":"10.1080","volume":"15","author":[{"given":"Hala T","family":"Borno","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of California at San Francisco, CA94158, USA"},{"name":"Helen Diller Family Comprehensive Cancer Center, Department of Medicine, University of California at San Francisco, CA94158, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J","family":"Small","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of California at San Francisco, CA94158, USA"},{"name":"Helen Diller Family Comprehensive Cancer Center, Department of Medicine, University of California at San Francisco, CA94158, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2018,11,14]]},"reference":[{"key":"e_1_3_4_3_1","unstructured":"Data S . Cancer stat facts: prostate cancer (2015). https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.2895"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1212299"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.09.049"},{"key":"e_1_3_4_7_1","author":"NCCN","unstructured":"NCCN . NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Prostate Cancer.www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf","journal-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Prostate Cancer."},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71205-7"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1201546"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-016-1803-9"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.4487"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.11.002"},{"key":"e_1_3_4_14_1","article-title":"Managing nonmetastatic castration-resistant prostate cancer","author":"Mateo J","year":"2018","unstructured":"Mateo J , FizaziK, GillessenSet al. Managing nonmetastatic castration-resistant prostate cancer. Eur. Urol. (2018).","journal-title":"Eur. Urol."},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.529"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt280"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.6716"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.10027.x"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2017.4"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eursup.2004.08.007"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-006-0203-x"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.05.015"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0000000000000105"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30784"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2014.70"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc4016"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601879"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3948"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1168175"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1207506"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209096"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3948"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715546"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.9987"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13896"},{"key":"e_1_3_4_36_1","unstructured":"The EuroQol Group . EQ-5D-3L User Guide: basic information on how to use the EQ-5D-3L instrument (2015). https:\/\/euroqol.org\/wp-content\/uploads\/2016\/09\/EQ-5D-3L_UserGuide_2015.pdf"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30456-X"},{"key":"e_1_3_4_38_1","unstructured":"Erleada H.o.p.i. Erleada (apalutamide tablets) prescribing information. Janssen Ortho LLC Gurabo PR 00778 2018 (2018)."},{"key":"e_1_3_4_39_1","unstructured":"US FDA . FDA approves apalutamide for non-metastatic castration-resistant prostate cancer. www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm596796.htm."},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14374"},{"key":"e_1_3_4_41_1","first-page":"1","volume-title":"Genitourinary Cancers","author":"Marzouk K","year":"2018","unstructured":"Marzouk K , EhdaieB. New imaging techniques in prostate cancer. In: Genitourinary Cancers. DaneshmandS, ChanKG (Eds). Springer International Publishing, Cham, Switzerland, 1\u201313 (2018)."},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/SPC.0000000000000371"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm972"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0142"},{"issue":"13","key":"e_1_3_4_45_1","first-page":"2605","article-title":"Abstract 2605: androgen receptor (AR) anomalies and efficacy of apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the Phase III SPARTAN study","volume":"78","author":"Matthew R","year":"2018","unstructured":"Matthew R , SmithST, SimonChowdhury, DavidOlmoset al. Abstract 2605: androgen receptor (AR) anomalies and efficacy of apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the Phase III SPARTAN study. Cancer Res.78(13 Suppl.), 2605 (2018).","journal-title":"Cancer Res."},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13526"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3729-z"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800536"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13137"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2018-0546","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:45:21Z","timestamp":1719125121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2018-0546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,14]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,2,28]]}},"alternative-id":["10.2217\/fon-2018-0546"],"URL":"https:\/\/doi.org\/10.2217\/fon-2018-0546","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-07-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}